Latest news
Neurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 17:19:41 GMTNeurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study - AllSciAllSci · Fri, 07 Aug 2026 16:26:00 GMTExperts Uncertain of GLP-1s’ Long-Term Clinical Benefits - Drug TopicsDrug Topics · Fri, 07 Aug 2026 15:09:05 GMTGIP EXPANDS NATIONAL INFRASTRUCTURE FOOTPRINT WITH MORE THAN $5 BILLION IN AWARDED PROJECTS - PR Newswire CanadaPR Newswire Canada · Thu, 06 Aug 2026 11:00:00 GMTCould GLP-1 Drugs Lower Heart Attack Risk? - Technology NetworksTechnology Networks · Wed, 05 Aug 2026 22:47:00 GMTAndrew Ambrosy, Top Heart Doctor, Highlights GLP-1 and Dual GIP/GLP-1 Use for Lowering Risk of Cardiovascular Attack - Yahoo FinanceYahoo Finance · Mon, 03 Aug 2026 13:00:00 GMTLatham & Watkins Advises on GIP’s US$580 Million Private Placement Financing - Latham & Watkins LLPLatham & Watkins LLP · Sat, 01 Aug 2026 04:14:50 GMT